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CD55 is a glycosylphosphatidylinositol-anchored protein, which inhibits complement activation by
acting on the complement C3 convertases. CD55 is widely localized in the cholesterol rich regions of the
cell plasma membrane termed membrane rafts. CD55 is attached to these specialized regions via a GPI
link on the outer leaﬂet of the plasma membrane. Membrane rafts anchor many important signaling
proteins, which control several cellular functions within the cell. For example, we recently demonstrated
that the membrane raft protein and complement inhibitor CD59 also controls insulin secretion by an
intracellular mechanism. Therefore, we have in this study aimed at addressing the expression and
function of CD55 in pancreatic beta cells. To this end, we observe that CD55 is highly expressed in INS1
832/13 beta cells as well as human pancreatic islets. Diabetic human islets show a tendency for increased
expression of CD55 when compared to the healthy controls. Importantly, silencing of CD55 in INS1 832/
13 cells does not affect their insulin secretory capacity. On the other hand, silencing of CD55 diminished
the intensity of membrane rafts as determined by Atto-SM staining. We hence conclude that CD55
expression is affected by glycemic status in human islets and plays a critical role in maintaining the
conserved structure of rafts in pancreatic islets, which is similar to that of the related complement in-
hibitor CD59. However CD55 does not interfere with insulin secretion in beta cells, which is in sharp
contrast to the action of the complement inhibitor CD59.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Type 2 diabetes (T2D) is caused by interplay between increased
insulin resistance in target tissues and failure of compensatory up-
regulation of insulin secretion in the pancreatic islets. Insulin
resistance develops as a result of excess caloric intake, sedentary
life style or as a consequence of ageing, but normoglycemia is
maintained as long as the b cells are capable of secreting higher
amounts of insulin in a biphasic manner. This imposes an extra
stress on the b cells and individuals with an inherited reduced
maximal capacity for insulin release develop T2D [1]. Inﬂammatory
processes are increasingly recognized as an important part of the
pathogenesis of the disease. The immune system is classiﬁed into
the adaptive and innate immune systems, which remain in tightnt of Clinical Sciences Malm€o,
, Sweden.
r€om).
r Inc. This is an open access articlcooperation [2]. In T2D it is the innate immune system that exhibits
increased chronic activity. The underlying cause of this auto-
inﬂammation remains only partially elucidated, but it results in
elevated levels of chemokines and cytokines. As a consequence,
insulin signaling is impaired, which leads to overall insulin resis-
tance [3]. Activation of the innate immune system coupled with
adipose tissue inﬂammation, as well as increased IL-1b signaling in
islets; both contribute to the pathogenesis of T2D [1,4,5].
The innate immune system comprising of cells such as macro-
phages, as well as soluble components such as the proteins of the
complement system, acts as the ﬁrst line of defence against
invading pathogens. Complement includes 30 membrane associ-
ated and plasma serum proteins, which together contribute to the
removal of pathogens and damaged tissue via a complex cascade of
events [2]. Complement provides efﬁcient defence but it can also
cause signiﬁcant damage to the self-tissue, hence under physio-
logical conditions it is a tightly controlled process. Three important
membrane bound inhibitors, CD46, CD55 and CD59 aid ine under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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accelerating factor, is attached to the outer plasma membrane via a
glycosylphosphatidylinositol (GPI) anchor. CD55 inhibits comple-
ment activation accelerating decay of pre-formed C3 and C5 con-
vertases, enzymatic complexes crucial for propagation of the
complement cascade [6,7]. Many studies have shown that activa-
tion of complement may occur in diabetic patients and that cells
treated with high glucose may trigger complement activation [8].
Many signaling GPI anchored proteins are localized to cholesterol
and sphingolipid rich patches of the plasma membrane known as
membrane rafts. Membrane rafts are highly dynamic structures
with a high degree of lateral mobility in the loosely ordered
membrane glycerophospholipids and are enriched in signaling
proteins, as well as exocytotic signaling protein such as SNARE
protein [9]. Furthermore, a recent study has deciphered the role of
another GPI anchored complement inhibitor CD59 in regulation of
membrane raft integrity and for insulin exocytosis [10]. Interest-
ingly, CD55 is also localized to themembrane rafts areas in a variety
of cells [11] and therefore we here studied whether CD55 may play
analogous roles in membrane rafts formation and pancreatic islet
functions.
2. Materials and methods
2.1. Microarray in human pancreatic islets
RNA isolation from human islets was performed using the All-
Prep DNA/RNAMini kit (QIAGEN). The microarrays were performed
following the Affymetrix standard protocol for Human Gene 1.0 ST
whole transcript based assay.
Total RNAwas extracted from 131 islet cadaver donors and RNA-
seq libraries were generated using standard Illumina protocols
(TruSeq RNA sample preparation kit). Libraries were sequenced on
an Illumina HiSeq 2000 using paired-end chemistry and 100-bp
cycles to an average depth of 32 M read pairs/sample. Reads were
aligned to hg19 using STAR (version 2.4, [12]) and read count
calculated by HTSeq-count and normalized using trimmed mean of
M-values. Statistical inference for RNA-seq data was performed
using the R-package ‘limma’. Isoform abundances were calculated
using RSEM (version 1.2.18, [13]).
2.2. Flow cytometry of human islet cells
Human islets were dispersed to single cell suspension using
Accutase (Life Technology). The dispersed islet cells were ﬁxed and
permeabilized before the ﬂow cytometric analysis. Levels of intra-
cellular insulin and glucagonwere measured using anti-insulin and
anti-glucagon antibodies (R&D Systems), which were conjugated
with R-phycoerythrin and allophycocyanin respectively by the
Lightening- Link technology (Innova Bioscience, Cambridge, United
Kingdom). Flow cytometry data were acquired on a CyAN ADP
(Beckman Coulter) and analysed using FlowJo software (TreeStar,
Ashland, OR, USA).
2.3. Cell culture and siRNA transfection
INS1832/13 cellswere cultured in RPMI 1640 containing 11.1mM
D-glucose supplemented with 10% fetal bovine serum, 100 U/ml
penicillin,100 mg/ml streptomycin, and25 mM2-mercaptoethanol, at
37 C in a humidiﬁed atmosphere containing 95% air and 5% CO2.
Human lung carcinoma epithelial A549 cellswere cultured inDMEM
containing 25 mM D-glucose supplemented with 10% FCS, 100 U/ml
penicillin, 100 mg/ml streptomycin at 37 C in a humidiﬁed atmo-
sphere containing 95% air and 5% CO2. CD55 siRNA (30 nM) wastransiently transfected using Dharmafect (Dharmacon) according to
the manufacturer's protocol in both cell types.
2.4. Gene expression analysis
RNA was extracted using the RNeasy Kit (QIAGEN). RNA (1 mg)
was used for cDNA synthesis with SuperScript III (Invitrogen). Re-
action mixture (10 ml) with 50 ng cDNA, 5 ml TaqMan mastermix
and 900 nM TaqMan gene expression assay were run on a 7900HT
Fast Real-Time System (Applied Biosystem). Primers of CD55 and
housekeeping gene HPRT1 (Applied Biosystems, USA) tagged with
FAM dyes were used for ampliﬁcation detection.
2.5. Flow cytometry
After 72 h of transfection with siRNA, INS1 832/13 cells were
harvested by trypsinization and incubated with saturating amounts
of anti-rat CD55 (Hycult), or isotype control antibodies in FACS
binding buffer (150mMNaCl,10mMHEPES pH 7.4, 5mMKCl, 2 mM
CaCl2, 0.5% BSA, 30 mM NaN3) for 30 min at 4 C. Cells were then
washed once in FACS binding buffer and then resuspended in FACS
binding buffer with 1:200 FITC-labeled goat anti-mouse Fab’ frag-
ments (DAKO) for 30 min at 4 C, before washing again in FACS
bindingbuffer andassessingﬂuorescencebyﬂowcytometry (Partec).
2.6. Insulin secretion
INS1 832/13 cells were cultured in 24-well dishes and trans-
fected with siRNA for 72 h before assay. When assayed, the cells
were washed in KrebseRinger bicarbonate buffer, pH 7.4, supple-
mented with 10 mM HEPES, 0.1% BSA and preincubated in 2.8 mM
glucose buffer for 120 min at 37 C. Insulin secretion was then
induced by static incubation of the cells for 1 h in 1 ml buffer
containing 2.8 or 16.7 mM glucose combined with 10 mM a-KIC or
35 mM Kþ, respectively. Insulin from INS1 832/13 cells was
measured by the Coat-a-Count RIA (Siemens Healthcare Di-
agnostics, Deerﬁeld, IL).
2.7. Membrane raft staining
INS1 832/13 and A549 cells seeded on 35 mm glass-bottom
dishes cultured were stained with Atto-SM (ATTO 647N- Sphin-
gomyelin, 10 mM in HDMEM; ATTO-tec, Germany) for 20 min on ice.
2.8. Immunostaining
Cells were ﬁrst washed twice and ﬁxed with 3% PFA in PBS for
5 min and 10 min respectively, followed by permeabilization with
0.1% Triton-X 100 for 30 min or not (Non-pearmeabilization). The
blocking solution containing 5% normal donkey serum in PBS was
incubatedwith the cells for 15min. Primaryantibodies against CD55
(Hycult Biotech) and Insulin (Europroxima)were diluted in blocking
solution and incubated overnight at 4 C. Immunoreactivity was
performedusingﬂuorescently labeled secondary antibodies (1:400)
and visualized byconfocalmicroscopy (Carl Zeiss, Germany). During
the analysis, all the images were captured using the same settings
and exposure times to allow a comparison between the samples.
3. Results
3.1. Expression of complement genes in INS1 832/13 cells, human
and rat islets
The expression of the complement genes in insulin secreting rat
INS1 832/13 cells was studied by qPCR. Among the 18 genes
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CD55 was the secondmost highly expressed gene (Fig. 1A). A recent
publication has shown that CD55 is expressed in pancreatic human
islets and also in Wistar and diabetic GK rat islets [10]. Further, in
the same study it was observed that expression of CD55 had a
tendency for increase in the diabetic (GK) rat islets as compared to
the healthy control (Wistar) islets. Interestingly, our microarray
analysis showed a similar increase in pancreatic islets from human
donors. The diabetic human islets (HbA1c > 6.0, n ¼ 45) expressed
higher levels of CD55 compared to the healthy control islets
(HbA1c < 6.0, n ¼ 86) (p < 0.05; Fig. 1B). Finally, human islets
showed increased expression of CD55 response to glucose incu-
bation (24 h, 18.9 mM glc; Fig. 1C). These results clearly show that
CD55 is expressed in the insulin secreting cells and islets, and
indicate that the CD55 expression level may be changed under
diabetic conditions.
3.2. Gene expression proﬁling of CD55
The mRNA expression proﬁle (RNA sequencing) of CD55 was
interrogated in a set of 131 human pancreatic islets sequenced as
part of the Nordic Islet Transplantation Program/ExoDiab. CD55
was found to be highly expressed in human islets (higher expres-
sion than 90.4% of all RefSeq genes; Fig. 2A). CD55 expression was
upregulated in diabetic donors (nominal p-value: 0.0062; Fig. 2B)
and was also positively correlated with HbA1c (p ¼ 0.025; Fig. 2C).
Enseml (GrCh38, accession id ENSG00000196352) reports 9
transcripts/splice variants for CD55, 5 of which are robustly
expressed (10 > FPKM) in pancreatic islets (Fig. 2D). All ﬁve tran-
scripts encode proteins that differ in length between 326 and 550
amino acids, differing primarily in expression of exon 5 and exon 10
and the length of the UTR. One transcript (ENST00000367067) was
shown to increase in relative transcript abundance in the totalFig. 1. CD55 is expressed in human and rat-derived pancreatic cells. A. Complement gene e
analysed by qPCR. B. CD55 expression in pancreatic islets from human donors [n ¼ 86 (HbA1
in response to 5.5 mM and 18.9 mM glucose concentration analysed by RNA sequencing.CD55 transcript pool in diabetic donors (Fig. 2E) as well as under
high glucose condition (Fig. 2F), indicating an alternative-splicing
event.
3.3. Insulin secretion is unaffected by silencing of CD55
The primary physiological function of pancreatic b cells is in-
sulin secretion. To scrutinize if CD55 may play a role in insulin
secretion, we down regulated CD55 expression in INS1 832/13 cells
by RNA interference. QPCR showed that CD55 was efﬁciently down
regulated on the mRNA level (Fig. 3A). CD55 was also down regu-
lated by 50% at the protein level, as quantiﬁed by staining with
speciﬁc antibodies and analysis by ﬂow cytometry (Fig. 3B). We
next analysed insulin secretion in INS1 832/13 cells in response to
2.8 and 16.7 mM glucose after 72 h of CD55 knockdown (Fig. 3C).
Down-regulation of CD55 had no effect on either the basal or
stimulated conditions as compared to inactive siRNA as control
(siControl). We next explored whether CD55 down-regulation has
any effect at other stages of the stimulus secretion-coupling
pathway. To this end, we complemented the incubations in high
glucose that assess the entire b cell stimulus-secretion coupling (i.e.
glucose transport, glycolysis, mitochondrial oxidation, initiation of
electrical activity and ﬁnally, exocytosis) with incubations using the
mitochondrial substrate a-KIC and 35 mM Kþ. a-KIC enters the
Krebs cycle directly, whereas Kþ bypasses glucose metabolism
completely and depolarizes the plasma membrane directly,
resulting in activation of voltage gated Ca2þ channels that trigger
insulin release. For all conditions tested, CD55 silencing exerted a
modest, but insigniﬁcant, inhibition of insulin secretion. However,
in human islets we observed a weak negative correlation between
CD55 expression and glucose-stimulated insulin secretion
(expressed as stimulation index; SI or fold change; Fig. 3D). Taken
together, these results fail to support a role for CD55 in the controlxpression in INS1 832/13 cells. CD55 is the second most highly expressed gene (n ¼ 3)
c < 6.0), 45 (HbA1c > 6.0)] analysed by microarray. C. The difference in CD55 expression
Fig. 2. CD55 expression in metabolic tissues and in relation to glycemic status. A. CD55 expression in different tissues. B. CD55 expression in diabetic patients in comparison to
controls. C. Correlation of CD55 with HbA1c. D. Different isoforms of CD55. E. Expression of isoform ENST00000367067 in the presence (1) and absence (2) of diabetes. F. Expression
of isoform ENST00000367067 under high and low glucose stimulation conditions.
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tween CD55 and CD59 [10] as to their roles in this respect.
3.4. CD55 plays an important role in maintaining the membrane
raft integrity
Pancreatic b cells, as well as INS1 832/13 cells, express choles-
terol and sphingolipid rich membrane rafts in the plasma mem-
brane [10]. Many signaling and exocytotic proteins are localized to
these specialized regions [9]. It is known that the GPI-linked CD55protein is co-puriﬁed with membrane raft proteins in a variety of
cells [14,15]. Given our previous observation to the effect that CD59
is important for membrane raft stability in endocrine cells [10], we
next investigated whether CD55 also has similar effects on mem-
brane raft integrity. To address this, we stained the raft component
sphingomyelin with Atto-SM [16] in CD55 down regulated INS1
832/13 cells (Fig. 4A). Interestingly, we observed that the cells with
CD55 knockdown exhibited decreased ﬂuorescent intensity of Atto-
SM when compared to the controls (n ¼ 3, p < 0.05; Fig. 4B).
Further, to check if this effect of CD55 knockdown on rafts holds
Fig. 3. CD55 silencing does not affect insulin secretion. A. Validation of the siRNA used against CD55. CD55 mRNA levels relative to HPRT in clonal cells treated with the siControl or
siCD55, after 72 h of transfection (p < 0.01, n ¼ 3). B. Protein level expression of CD55 after silencing for 72 h, analysed by ﬂow cytometry (p < 0.05, n ¼ 3). C. Insulin secretion in
INS1 832/13 cells after CD55 silencing measured under stimulation with 2.8 or 16.7 mM glucose concentrations (n ¼ 3) with or without a-KIC and 35 mM Kþ in comparison to the
siControl treated cells. D. The correlation of CD55 with insulin secretion index (SI index) in islets from 125 healthy individuals.
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epithelial A549 cells (Fig. 4C). These cells also exhibited decreased
raft staining intensity after CD55 silencing compared to the corre-
sponding controls (n ¼ 3, p < 0.01; Fig. 4D). Collectively, these re-
sults show that CD55 is an important contributor to the integrity of
membrane rafts.
4. Discussion
In this study we have investigated the expression and role of
CD55 in pancreatic b cells. The main ﬁnding of our study is that
CD55 is a highly expressed gene in b cells, which contributes to
maintaining the structural architecture of the membrane rafts. We
also found that CD55 plays no major role in regulating the insulin
exocytosis process in the b cells, which is in sharp contrast to CD59,
another GPI linked complement inhibitor.
4.1. CD55 expression in relation to glycemic status
The presence of CD55 in pancreatic islets and cells suggests that
it plays an important role in protecting the cells from autologous
complement attack. Pancreatic islets from diabetic human donors
exhibited increased levels of CD55 mRNA, in comparison to the
healthy control islets and incubation of human islets in high
glucose resulted in increase of CD55 mRNA expression. On the
converse, we observe that the expression of CD55 in insulinsecreting INS1832/13 cells remained unchanged or showed a slight
tendency for an increase after culture in high glucose (Fig. S1). This
discrepancy may either be explained by species differences, or if
other pancreatic cells such as a or d cells are the main sources of
increased CD55 expression in intact human islets. To determine the
cellular origin of human islets CD55, the expression of CD55 was
correlated with the proportion of a and b cells in 30 human islet
samples as measured by ﬂow cytometry. However, CD55 had a
weak, negative correlation with both insulin and glucagon (0.17
and0.15 respectively, both p > 0.3; Fig. S2), indicating that CD55 is
probably not speciﬁc to neither the a cells nor the b cells.4.2. CD55 is not functionally associated with the exocytotic
machinery
One important aim of this study was to decipher the role of
CD55 in insulin secretion. This was of particular interest consid-
ering that GPI-linked CD59 was recently shown to interact with
SNARE proteins and to be necessary for insulin secretion. In
contrast, CD55, despite being the second most highly expressed
complement gene in INS1 821/13 cells, does not seem to be
involved in the secretory function of these cells. This clearly in-
dicates that the effect of CD59 is highly speciﬁc, a fact perhaps
explained by the co-localization of CD59 with the exocytotic pro-
teins, which may be lacking with CD55. This hypothesis is further
Fig. 4. CD55 is important for maintaining membrane raft integrity. A. Staining of
membrane rafts in INS1 832/13 cells with Atto-SM in cells treated either with siControl
or siCD55. B. CD55 silencing signiﬁcantly decreases the mean ﬂuorescence intensity of
Atto-SM (p < 0.05, n ¼ 3). C. Staining of membrane rafts in A549 cells with Atto-SM in
cells treated either with siControl or siCD55 D. CD55 silencing signiﬁcantly decreases
the mean ﬂuorescence intensity of Atto-SM (p < 0.05, n ¼ 3).
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CD55 and insulin do not co-localize (Fig. S3).4.3. CD55 controls membrane raft organization
Membrane rafts are highly dynamic cholesterol and sphingoli-
pid rich structures found in the plasma membrane of living cells.
These structures hold many GPI anchored proteins and also pro-
teins necessary for insulin exocytotic events like SNAP-25 and
syntaxin. Earlier reports indicated that CD55 is localized to mem-
brane rafts [14,15]. Here we showed that silencing of CD55 signif-
icantly compromises the integrity of the membrane rafts. This
effect is not limited only to the pancreatic b cells, as a similar
observation is also made for A549 epithelial cells. This clearly
shows us that deregulation of one GPI protein in these highly
conserved regions can cause deleterious effects to its native state of
conﬁguration. A similar GPI-linked complement inhibitor CD59 is
also proved to be important for raft stability [10]. Hence, we could
conclude that both CD55 and CD59 are important for maintaining
raft structural integrity.4.4. Comparison of CD59 and CD55 actions in the b cell
It has been shown that disruption of native integrity of mem-
brane rafts inﬂuences the exocytotic capacity of insulin secreting b
cell ([9], manuscript in preparation) by regulating the embedded
exocytotic proteins. On the contrary, we here show that CD55
knockdown does not inﬂuence the exocytotic capacity. Silencing of
CD59 on the other hand, which is also a complement inhibitor was
found to decrease insulin secretion and was also found to
compromise the membrane raft integrity. The functional differ-
ences observed between these two proteins could be explained
simply by the 10-fold lower expression of CD55 in b cells, as
compared with CD59. However, the most likely explanation to the
discrepancy in terms of effects on insulin secretion is the afﬁnity of
CD59 to the exocytotic SNARE proteins. Membrane rafts anchor
many GPI linked proteins a well as the exocytotic proteins. The GPI
anchor composition and also the localization of GPI linked proteins
within the rafts in an important factor that decides their functional
consequences [17]. Our results in Fig. S3, indicate that CD55 is not
localized in the close proximity of the insulin granules and the
exocytotic proteins, which argues against it being a regulator of
insulin secretion, unlike CD59which is co-localized with exocytotic
proteins within the rafts. In conclusion, this study highlights the
speciﬁc functions of CD59 and CD55 in the beta cell; pointing out
that GPI linked proteins possess speciﬁc functionalities.
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